Prochlorperazine is Contraindicated in Parkinson's Disease
Prochlorperazine should NOT be used in patients with Parkinson's disease due to the high risk of extrapyramidal symptoms (EPS) and worsening of motor function. 1
Specific Contraindication in Parkinson's Disease
- Haloperidol (a related first-generation antipsychotic) explicitly states: "Do not use if patient has Parkinson's disease or dementia with Lewy bodies due to risk of EPSEs" 1
- While this specific warning is documented for haloperidol in the ESMO guidelines, prochlorperazine shares the same mechanism (dopamine receptor antagonist) and carries identical risks 2
- Prochlorperazine was the most common offending drug causing drug-induced parkinsonism in elderly patients, accounting for 21 of 48 cases (44%) in one study, with 25% of affected patients unable to walk at presentation 3
- The FDA label for prochlorperazine confirms it is a dopamine receptor antagonist that causes CNS depression, anticholinergic effects, and extrapyramidal symptoms 4
Other Contraindications and Cautions for Prochlorperazine
Absolute Cautions (from FDA labeling):
- History of leukopenia or neutropenia - can cause drug-induced leukopenia/neutropenia; requires CBC monitoring 4
- Severe neutropenia (absolute neutrophil count < 1000/mm³) - must discontinue immediately 4
- Dementia - listed as a caution due to anticholinergic effects and EPS risk 2
- Glaucoma - use with caution due to anticholinergic effects and mydriasis 4
- Seizure disorder - phenothiazines lower the convulsive threshold 4
Cardiovascular Contraindications:
- Impaired cardiovascular systems - large doses and parenteral administration should be used cautiously due to hypotension risk 4
- Avoid epinephrine for treating hypotension as it may cause paradoxical further lowering of blood pressure 4
Drug Interactions:
- Propranolol - concomitant use results in increased plasma levels of both drugs 4
- Oral anticoagulants - phenothiazines may diminish their effect 4
- Anticonvulsants - may interfere with metabolism of phenytoin (Dilantin) 4
Clinical Pitfalls
- Masking of serious conditions: The antiemetic action may mask signs of drug overdosage, intestinal obstruction, brain tumor, or Reye's syndrome 4
- Post-surgical aspiration risk: Aspiration of vomitus has occurred in post-surgical patients receiving prochlorperazine 4
- Prolonged recovery: Drug-induced parkinsonism from prochlorperazine resolved in a mean of 7 weeks but ranged from 1 to 36 weeks 3
- Unmasking latent disease: 5 cases initially resolved but developed idiopathic parkinsonism after 3-18 months, suggesting the drug may unmask latent disease 3
Safer Alternatives for Nausea in Parkinson's Disease
- Ondansetron (5-HT3 antagonist) - does not affect dopamine receptors 2
- Domperidone (where available) - peripheral dopamine antagonist that doesn't cross blood-brain barrier
- Trimethobenzamide - alternative antiemetic with less EPS risk